Patients develop immune reaction to Eprex.
D002986:Clinical Trials as Topic; D004345:Drug Industry; D064420:Drug-Related Side Effects and Adverse Reactions / Q000097:blood*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006801:Humans; D007262:Infusions, Intravenous; D015995:Prevalence; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000453:epidemiology / Q000276:immunology*; D018570:Risk Assessment
D011994:Recombinant Proteins; D004921:Erythropoietin